US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicus Pharma Ltd.

2.61

-0.1800-6.45%

Volume:116.51K

Turnover:309.59K

Market Cap:41.32M

PE:- -

High:2.78

Open:2.72

Low:2.55

Close:2.79

Loading ...

Overview Company News Filings

Medicus Pharma Ltd. Announces Binding Letter of Intent to Acquire UK Biotech Firm Antev Ltd

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Submits Product Development Plan to FDA for Treating Squamous Cell Carcinoma in Horses with D-MNA Patch

Medicus Pharma Ltd. Dismisses EisnerAmper Amid Concerns Over "Going Concern" Status

Medicus Pharma Ltd. Completes $7 Million Public Offering to Fund Basal Cell Carcinoma Clinical Trials

Quantum Biopharma Receives $2.35 Million USD From a Mutually-Agreed Global Legal Settlement With DR. Raza Bokhari

THOMSON REUTERS

Medicus Pharma Ltd. Announces $7 Million Public Offering of Shares and Warrants

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd - Files for of Offering 1.4 Mln Units - SEC Filing

THOMSON REUTERS

BRIEF-Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares

Medicus Pharma Ltd: Files for Resale From Time to Time of up to 3.7 Mln Common Shares by Ya Ii Pn, Ltd-SEC Filing

THOMSON REUTERS

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Announces Binding Agreement to Acquire UK Biotech Firm Antev Ltd

Major Shareholder Sells Off Huge Chunk of Medicus Pharma Stock!

Velocity Fund Partners, LP Reports Disposal of Common Shares of Medicus Pharma Ltd

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Is Maintained at Buy by Maxim Group

Medicus Pharma price target raised to $20 from $10 at Maxim

BRIEF-Medicus Pharma Ltd To Acquire Antev Ltd. For $75 Million In A Share Exchange Transaction

Medicus Pharma: Antev Shareholders to Receive About 19% Stake in Medicus and $65 Million in Contingent Payments

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":2.61,"timestamp":1749841427418,"preClose":2.79,"halted":0,"volume":116513,"delay":0,"floatShares":6964800,"shares":15832737,"eps":0,"marketStatus":"Trading","change":-0.18,"latestTime":"06-13 15:04:20 EDT","open":2.72,"high":2.775,"low":2.55,"amount":309585.49221610004,"amplitude":0.080645,"askPrice":2.7,"askSize":254,"bidPrice":2.6,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749844800000},"marketStatusCode":2,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":2.79,"preHourTrading":{"tag":"盘前","latestPrice":2.72,"preClose":2.79,"latestTime":"09:29 EDT","volume":1139,"amount":3133.0749777,"timestamp":1749821346303},"postHourTrading":{"tag":"盘后","latestPrice":2.79,"preClose":2.79,"latestTime":"19:11 EDT","volume":1831,"amount":5137.41,"timestamp":1749769906296},"volumeRatio":0.447803},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":6964800,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.447803,"shares":15832737,"dividePrice":0,"high":2.775,"amplitude":0.080645,"preClose":2.79,"low":2.55,"week52Low":1.8,"pbRate":"--","week52High":8.94,"institutionHeld":0,"latestPrice":2.61,"committee":-0.118943,"eps":0,"divideRate":0,"volume":116513,"delay":0,"ttmEps":0,"open":2.72,"prevYearClose":2.43,"prevWeekClose":2.76,"prevMonthClose":2.55,"prevQuarterClose":3.72,"fiveDayClose":2.76,"twentyDayClose":5.95,"sixtyDayClose":3.11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542151667","title":"Medicus Pharma Ltd. Announces Binding Letter of Intent to Acquire UK Biotech Firm Antev Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2542151667","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542151667?lang=en_us&edition=fundamental","pubTime":"2025-06-12 19:31","pubTimestamp":1749727878,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the signing of a binding letter of intent to acquire Antev Ltd., a UK-based late clinical stage biotech company. Antev is developing Teverelix, a next-generation GnRH antagonist aimed at providing a first-in-market treatment for cardiovascular high-risk advanced prostate cancer patients and those experiencing first acute urinary retention relapse episodes due to an enlarged prostate. This acquisition marks a significant step for Medicus Pharma in expanding its portfolio and strengthening its position in the biotech industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on June 12, 2025, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL6bRCRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2542333762","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2542333762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542333762?lang=en_us&edition=fundamental","pubTime":"2025-06-09 22:47","pubTimestamp":1749480420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2025 10:47 ET (14:47 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2542056389","title":"Medicus Pharma Ltd. Submits Product Development Plan to FDA for Treating Squamous Cell Carcinoma in Horses with D-MNA Patch","url":"https://stock-news.laohu8.com/highlight/detail?id=2542056389","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542056389?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:31","pubTimestamp":1749468665,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the submission of a comprehensive product development plan to the Food and Drug Administration  to treat external squamous cell carcinoma  in horses. This plan involves the use of a novel Doxorubicin-containing microneedle array  patch, which in December 2024 received a Minor Use in Major Species Designation . The submission aims to seek the FDA's concurrence under the MUMS designation, advancing the company's efforts in veterinary oncology. This development is part of Medicus Pharma's broader initiative to innovate treatment options in veterinary medicine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL4VtW0k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2541300581","title":"Medicus Pharma Ltd. Dismisses EisnerAmper Amid Concerns Over \"Going Concern\" Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2541300581","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541300581?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:06","pubTimestamp":1749153971,"startTime":"0","endTime":"0","summary":"**Medicus Pharma Ltd. Announces Change in Certifying Accountants Amidst Financial Concerns** June 5, 2025 - Medicus Pharma Ltd. has announced the dismissal of EisnerAmper LLP as its independent registered public accounting firm, following a recommendation by the company's audit committee and approval by the board of directors. The decision comes after EisnerAmper raised concerns about the company's ability to continue as a going concern due to negative cash flows and operating losses. EisnerAmper's report for the fiscal year ending December 31, 2024, highlighted substantial doubt about Medicus Pharma's financial stability, although it did not issue an adverse opinion or disclaimer. Despite these concerns, there were no disagreements between the company and EisnerAmper on accounting principles or practices. KPMG LLP has been appointed as the new independent registered public accounting firm, with EisnerAmper authorized to fully cooperate with the transition. This change follows disclosu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL3r0Zlj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Medicus Pharma Ltd. Dismisses EisnerAmper Amid Concerns Over \"Going Concern\" Status","news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2540797434","title":"Medicus Pharma Ltd. Completes $7 Million Public Offering to Fund Basal Cell Carcinoma Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2540797434","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540797434?lang=en_us&edition=fundamental","pubTime":"2025-06-03 01:41","pubTimestamp":1748886066,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has successfully closed its public offering, raising $7.0 million. The company issued 2,260,000 units at a price of $3.10 per unit, with each unit comprising one common share and one warrant to purchase an additional share. The warrants have an exercise price of $3.10 and will expire in five years. Maxim Group LLC served as the lead placement agent, with Brookline Capital Markets and D. Boral Capital as co-placement agents. The proceeds from the offering are intended to fund a Phase 2 clinical trial for basal cell carcinoma treatment using a dissolvable microarray needle skin patch, with potential expansion to other skin disease trials and general corporate purposes. The common shares are traded under the symbol \"MDCX\" on the Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL5xnfpp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2539267752","title":"Quantum Biopharma Receives $2.35 Million USD From a Mutually-Agreed Global Legal Settlement With DR. Raza Bokhari","url":"https://stock-news.laohu8.com/highlight/detail?id=2539267752","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539267752?lang=en_us&edition=fundamental","pubTime":"2025-05-30 19:00","pubTimestamp":1748602800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA5SVMQM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2539297934","title":"Medicus Pharma Ltd. Announces $7 Million Public Offering of Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2539297934","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539297934?lang=en_us&edition=fundamental","pubTime":"2025-05-30 08:31","pubTimestamp":1748565070,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the pricing of its public offering, raising $7.0 million through the issuance of 2,260,000 units at $3.10 per unit. Each unit includes one common share and one warrant, which can be exercised to purchase an additional common share at the same price within five years. The offering is led by Maxim Group LLC, with Brookline Capital Markets and D. Boral Capital as co-placement agents. The common shares are listed on NASDAQ under the symbol \"MDCX,\" while the warrants will not be traded on any securities exchange. Proceeds from this offering are earmarked for advancing the company's clinical trials related to basal cell carcinoma and potentially expanding trials to other non-melanoma skin diseases, with remaining funds allocated for general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL1TW9s7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2539268413","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2539268413","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539268413?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:54","pubTimestamp":1748523240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2025 08:54 ET (12:54 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2538923674","title":"Medicus Pharma Ltd - Files for of Offering 1.4 Mln Units - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2538923674","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538923674?lang=en_us&edition=fundamental","pubTime":"2025-05-28 05:00","pubTimestamp":1748379625,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ1ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2538496538","title":"BRIEF-Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2538496538","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538496538?lang=en_us&edition=fundamental","pubTime":"2025-05-28 01:34","pubTimestamp":1748367272,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common SharesMay 27 (Reuters) - Medicus Pharma Ltd MDCX.O:MEDICUS PHARMA LTD: FILES FOR RESALE FROM TIME TO TIME OF UP TO 3.7 MILLION COMMON SHARES BY YA II PN, LTD-SEC FILING ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ142:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2538449501","title":"Medicus Pharma Ltd: Files for Resale From Time to Time of up to 3.7 Mln Common Shares by Ya Ii Pn, Ltd-SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2538449501","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538449501?lang=en_us&edition=fundamental","pubTime":"2025-05-28 01:20","pubTimestamp":1748366454,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ142:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2537946486","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2537946486","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537946486?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:28","pubTimestamp":1747916880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 22, 2025 08:28 ET (12:28 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2537894391","title":"Medicus Pharma Ltd. Announces Binding Agreement to Acquire UK Biotech Firm Antev Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2537894391","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537894391?lang=en_us&edition=fundamental","pubTime":"2025-05-22 19:31","pubTimestamp":1747913470,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced a significant development in its strategic growth plan with the signing of a binding letter of intent to acquire Antev Ltd., a UK-based biotech company. Antev is in the late clinical stages of developing Teverelix, a next-generation GnRH antagonist, which is positioned as a first-in-market product for treating cardiovascular high-risk prostate cancer patients and those experiencing episodes of acute urinary retention due to an enlarged prostate. This acquisition aims to expand Medicus Pharma's portfolio and enhance its offerings in the pharmaceutical sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL8fQcrW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2537961090","title":"Major Shareholder Sells Off Huge Chunk of Medicus Pharma Stock!","url":"https://stock-news.laohu8.com/highlight/detail?id=2537961090","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537961090?lang=en_us&edition=fundamental","pubTime":"2025-05-22 10:08","pubTimestamp":1747879695,"startTime":"0","endTime":"0","summary":"New insider activity at Medicus Pharma Ltd ( ($MDCX) ) has taken place on May 22, 2025. Significant shareholder VELOCITY FUND PARTNERS, LP has dive...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-shareholder-sells-off-huge-chunk-of-medicus-pharma-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-shareholder-sells-off-huge-chunk-of-medicus-pharma-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2537693008","title":"Velocity Fund Partners, LP Reports Disposal of Common Shares of Medicus Pharma Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2537693008","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537693008?lang=en_us&edition=fundamental","pubTime":"2025-05-22 00:57","pubTimestamp":1747846663,"startTime":"0","endTime":"0","summary":"Velocity Fund Partners, LP has reported a disposal of common shares of Medicus Pharma Ltd. The form was filed by Velocity Fund Partners, LP along with other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL5zg2RW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2534229643","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2534229643","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534229643?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:28","pubTimestamp":1747049280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2025 07:28 ET (11:28 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2534157503","title":"Medicus Pharma Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2534157503","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534157503?lang=en_us&edition=fundamental","pubTime":"2025-05-09 02:06","pubTimestamp":1746727560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2025 14:06 ET (18:06 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2533187476","title":"Medicus Pharma price target raised to $20 from $10 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2533187476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533187476?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:39","pubTimestamp":1746707976,"startTime":"0","endTime":"0","summary":"Maxim raised the firm’s price target on Medicus Pharma (MDCX) to $20 from $10 and keeps a Buy rating on the shares. The firm cites the company’s An...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-price-target-raised-to-20-from-10-at-maxim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-price-target-raised-to-20-from-10-at-maxim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"gpt_icon":0},{"id":"2530285664","title":"BRIEF-Medicus Pharma Ltd To Acquire Antev Ltd. For $75 Million In A Share Exchange Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2530285664","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530285664?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:31","pubTimestamp":1745847065,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Ltd To Acquire Antev Ltd. For $75 Million In A Share Exchange TransactionMedicus Pharma Ltd MDCX.O:MEDICUS PHARMA LTD: TO ACQUIRE ANTEV LTD. FOR $75 MILLION IN A SHARE EXCHANGE TRANSACTIONMEDICUS PHARMA: ANTEV SHAREHOLDERS TO RECEIVE ABOUT 19%  STAKE IN MEDICUS AND $65 MILLION IN CONTINGENT PAYMENTSSource text: [ID:n0001062993-25-008086]Further company coverage: MDCX.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R61O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2530283005","title":"Medicus Pharma: Antev Shareholders to Receive About 19%  Stake in Medicus and $65 Million in Contingent Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2530283005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530283005?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:28","pubTimestamp":1745846892,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R61O8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744689600000}}}